Medicine and Dentistry
Neoadjuvant Therapy
100%
Individualization
100%
Neoadjuvant Chemotherapy
75%
Breast Cancer
75%
Olaparib
50%
Tumor Biology
25%
Immunotherapy
25%
Estrogen Receptor
25%
Abemaciclib
25%
Capecitabine
25%
Hormone Receptor
25%
Triple Negative Breast Cancer
25%
Pembrolizumab
25%
Immune Checkpoint Inhibitor
25%
Pharmacology, Toxicology and Pharmaceutical Science
Breast Cancer
100%
Cyclin Dependent Kinase 4
33%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
33%
Immune Checkpoint Inhibitor
33%
Triple Negative Breast Cancer
33%
Hormone Receptor
33%
Capecitabine
33%
Neoplasm
33%
Pembrolizumab
33%